Patient characteristics
| Parameter . | Median (range) . | No. of patients (%) . |
|---|---|---|
| Patients | 22 | |
| Age, y | 29 (18-46) | |
| 30 or younger | 12 (55) | |
| Older than 30 | 10 (45) | |
| Sex | ||
| Male | 12 (55) | |
| Female | 10 (45) | |
| Weight, kg | 69.5 (41-85) | |
| Diagnosis | ||
| CML | 12 (45) | |
| CP1/CP2 | 6/2 | |
| AP/BC | 1/3 | |
| ALL | 6 (27) | |
| ALL in CR1 | 5 | |
| t(9;22) | 4 | |
| t(4;11) | 1 | |
| ALL in CR3 | 1 | |
| AML | 3 (14) | |
| Secondary AML in CR1 | 2 | |
| De novo AML in CR1 | 1 | |
| MDS | 1 (5) | |
| Time from diagnosis to CBT, mo | 10 (5-125) | |
| Time from the start of search to CBT, mo | 4 (0.25-12) | |
| Previous HSCT | 4 (18) | |
| Conditioning regimen | ||
| TT + BU + CY + ATG | 21 (95) | |
| FLU + TT + ATG | 1 (5) | |
| CMV serology | ||
| Positive | 17 (77) | |
| Negative | 5 (23) |
| Parameter . | Median (range) . | No. of patients (%) . |
|---|---|---|
| Patients | 22 | |
| Age, y | 29 (18-46) | |
| 30 or younger | 12 (55) | |
| Older than 30 | 10 (45) | |
| Sex | ||
| Male | 12 (55) | |
| Female | 10 (45) | |
| Weight, kg | 69.5 (41-85) | |
| Diagnosis | ||
| CML | 12 (45) | |
| CP1/CP2 | 6/2 | |
| AP/BC | 1/3 | |
| ALL | 6 (27) | |
| ALL in CR1 | 5 | |
| t(9;22) | 4 | |
| t(4;11) | 1 | |
| ALL in CR3 | 1 | |
| AML | 3 (14) | |
| Secondary AML in CR1 | 2 | |
| De novo AML in CR1 | 1 | |
| MDS | 1 (5) | |
| Time from diagnosis to CBT, mo | 10 (5-125) | |
| Time from the start of search to CBT, mo | 4 (0.25-12) | |
| Previous HSCT | 4 (18) | |
| Conditioning regimen | ||
| TT + BU + CY + ATG | 21 (95) | |
| FLU + TT + ATG | 1 (5) | |
| CMV serology | ||
| Positive | 17 (77) | |
| Negative | 5 (23) |
CP1 indicates first chronic phase; CP2, second chronic phase; AP, accelerated phase; BC, blast crisis; HSCT, hematopoietic stem cell transplantation; TT, thiotepa; BU, busulfan; CY, cyclophosphamide; and FLU, fludarabine.